You just read:

Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

News provided by

Questcor Pharmaceuticals, Inc.

Apr 21, 2014, 09:00 ET